Nov 04, 2019 / 01:15PM GMT
Presentation
Nov 04, 2019 / 01:15PM GMT
=====================
Corporate Participants
=====================
* Camilla Sylvest
Novo Nordisk A/S - Executive VP and Head of Commercial Strategy & Corporate Affairs
* Karsten Munk Knudsen
Novo Nordisk A/S - Executive VP & CFO
* Mads Krogsgaard Thomsen
Novo Nordisk A/S - Executive VP & Chief Science Officer
=====================
Conference Call Participants
=====================
* Jo Walton
Crédit Suisse AG, Research Division - MD
* Keyur Parekh
Goldman Sachs Group Inc., Research Division - Equity Analyst
* Peter Verdult
Citigroup Inc, Research Division - Director
* Peter James Welford
Jefferies LLC, Research Division - Senior Equity Analyst
* Simon P. Baker
Redburn (Europe) Limited, Research Division - Head of Pharmaceutical Research
* Stephen McGarry
HSBC, Research Division - Analyst
* Wimal Kapadia
Sanford C. Bernstein & Co., LLC., Research Division - Research
Novo Nordisk AS
(NYSE:NVO)
$
115.12
0.04 (0.03%)
Market Cap: 512.40 Bil
Enterprise Value: 511.58 Bil
PE Ratio: 38.75
PB Ratio: 30.80
GF Score: 97/100 Q3 2019 Novo Nordisk A/S Earnings Presentation Transcript
Nov 04, 2019 / 01:15PM GMT
Release Date Price:
$28.37
(+0.50%)
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers